Guru Sonpavde

2006–2025 年に発表

179
論文数
20,190
被引用数
77
h 指数
167
i10 指数

被引用数

Guru Sonpavde の年別被引用数2001 年: 被引用 1 件2008 年: 被引用 7 件2009 年: 被引用 16 件2010 年: 被引用 23 件2011 年: 被引用 18 件2012 年: 被引用 36 件2013 年: 被引用 56 件2014 年: 被引用 68 件2015 年: 被引用 87 件2016 年: 被引用 118 件2017 年: 被引用 158 件2018 年: 被引用 163 件2019 年: 被引用 631 件2020 年: 被引用 837 件2021 年: 被引用 895 件2022 年: 被引用 728 件2023 年: 被引用 599 件2024 年: 被引用 1,217 件2025 年: 被引用 578 件2026 年: 被引用 14 件2002〜2007 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,119 件、この内訳の 22.4%中国: 引用元論文 1,231 件、この内訳の 13%イタリア: 引用元論文 677 件、この内訳の 7.1%イギリス: 引用元論文 513 件、この内訳の 5.4%ドイツ: 引用元論文 449 件、この内訳の 4.7%日本: 引用元論文 407 件、この内訳の 4.3%フランス: 引用元論文 404 件、この内訳の 4.3%カナダ: 引用元論文 360 件、この内訳の 3.8%スペイン: 引用元論文 359 件、この内訳の 3.8%オランダ: 引用元論文 262 件、この内訳の 2.8%韓国: 引用元論文 206 件、この内訳の 2.2%スイス: 引用元論文 185 件、この内訳の 1.9%
0%22.4%その他 24.3%

分野

  • Medicine76.9%
  • Biochemistry, Genetics and Molecular Biology15.2%
  • Immunology and Microbiology4.9%
  • Computer Science0.6%
  • Neuroscience0.6%
  • Engineering0.4%
  • その他1.4%

トピック

  • Bladder and Urothelial Cancer Treatments8.4%
  • Cancer Immunotherapy and Biomarkers7.4%
  • Inflammatory Biomarkers in Disease Prognosis4.8%
  • Urinary and Genital Oncology Studies4%
  • Prostate Cancer Treatment and Research3.9%
  • Renal cell carcinoma treatment3.3%
  • その他68.2%

共著者

全論文

検索で開く
  1. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    著者: , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 1,155

  2. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

    著者: , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2014 被引用: 3,272

  3. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 462

  4. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    著者: , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 153

  5. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2020 被引用: 292

  6. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 688

  7. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma

    著者: , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 86

  8. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

    著者: , , , , , , , , , - European Urology 2018 被引用: 446

  9. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

    著者: , , , , , , , , , , - Cancer Immunology Research 2017 被引用: 476

  10. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shilpa Gupta, Matthew T. Campbell, Petros Grivas, Guru Sonpavde, Deepak Kilari, Ajjai Alva - Cancer 2021 被引用: 85

  11. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cecilia Mitchell, Alan W.C. Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, Jonathan E. Rosenberg - New England Journal of Medicine 2024 被引用: 145

  12. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jian Carrot‐Zhang, Alexander Gusev - Cancer Cell 2022 被引用: 116

  13. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

    著者: , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 129

  14. TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3β/β-catenin signalling

    著者: , , , , , , , , , , , , , , , , - Nature Communications 2022 被引用: 66

  15. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

    著者: , , , , , , , , , , - The Lancet Oncology 2011 被引用: 345

  16. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

    著者: , , , , , , , , , , , , , , , - Cancer 2020 被引用: 112

  17. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors

    著者: , , , , , , , , , , , , , , , , , , , - JCI Insight 2022 被引用: 65

  18. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Claire Drolen, Melissa G. Lechner, Alexandra Drakaki, Javier Baena, Caroline A. Nebhan, Tarek Haykal, Michael A. Morse, Alessio Cortellini, David J. Pinato, Alessia Dalla Pria, Evan Hall, Veli Bakalov, Nathan Bahary, Aarthi Rajkumar, Ankit Mangla, Vishal Shah, Parminder Singh, Frank Aboubakar Nana, Nerea Lopetegui‐Lia, Danai Dima, Ryan W. Dobbs, Pauline Funchain, Rabia Saleem, Rachel Woodford, Georgina V. Long, Alexander M. Menzies, Carlo Genova, Giulia Barletta, Sonam Puri, Vaia Florou, Damé Idossa, Maristella Saponara, Paola Queirolo, Giuseppe Lamberti, Alfredo Addeo, Melissa Bersanelli, Dory Freeman, Wanling Xie, Erin Reid, Elizabeth Y. Chiao, Elad Sharon, Douglas B. Johnson, Ramya Ramaswami, Mark Bower, Brinda Emu, Thomas U. Marron, Toni K. Choueiri, Lindsey R. Baden, Kathryn Lurain, Guru Sonpavde, Abdul Rafeh Naqash - Journal of Clinical Oncology 2023 被引用: 69

  19. Prostate Cancer, Version 1.2016

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dorothy A. Shead, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2016 被引用: 655

  20. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

    著者: , , , , , , , , - Annals of Oncology 2011 被引用: 290

  21. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sindhu Singh, Kevin M. Kane, Yull Arriaga, Amee Morgans, David D. Chism - The Journal of Urology 2019 被引用: 133

  22. Immune-Related Adverse Events with PD-1 Versus PD-L1 Inhibitors: A Meta-Analysis of 8730 Patients from Clinical Trials

    著者: , , , , - Future Oncology 2021 被引用: 102

  23. The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer

    著者: , , , , , - European Urology 2013 被引用: 198

  24. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

    著者: , , , , , , , , , , , - European Urology 2017 被引用: 142